Quantcast

Latest Amines Stories

High Dose Antidepressant Offers Some Hope For Alzheimer's Patients
2014-02-19 12:58:56

Brett Smith for redOrbit.com - Your Universe Online Agitation is a common symptom in patients with Alzheimer's disease and is associated with severe adverse consequences for both patients and caregivers. According to a new study published in JAMA, a high dose of the antidepressant citalopram considerably reduced agitation in patients with Alzheimer’s. However, the drug administered at this dose was also associated with mild adverse cognitive and cardiac effects – a sign that this...

2014-02-18 04:20:49

ALBANY, New York, February 18, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report " Cystic Fibrosis Therapeutics In Major Developed Markets To 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment And Market Growth" to its large collection of research reports....

2014-02-13 23:02:55

Comprehensive analysis and forecast on the melamine market at different geographical levels can be found in the in-demand research study “Melamine: 2014 World Market Outlook and Forecast up to 2018” prepared by Merchant Research & Consulting and recently published by Market Publishers Ltd. According to the report, in 2018, the global melamine supply is poised to surpass the 2 million tonnes mark. London, UK (PRWEB) February 13, 2014 During 2009-2010, unfavourable economic...

2014-01-29 16:28:52

MALVERN, Pa., Jan. 29, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today confirmed that the United States District Court for the District of Delaware ruled that United States Patent No. 5,464,864, Endo's patent covering frovatriptan, the active ingredient in FROVA(® )(frovatriptan succinate) tablets, is valid and infringed. The Court's decision prevents Mylan from marketing its generic version of FROVA(®) in the U.S. before Endo's patent expires November 8, 2015,...

2014-01-14 04:21:01

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio. "We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move...

2014-01-13 12:28:09

To combat the advance of painkiller abuse around the world, the leading supplement for withdrawal is going global AUSTIN, Texas, Jan. 13, 2014 /PRNewswire/ -- In an effort to combat global prescription drug abuse, Withdrawal Ease -- the leading nutritional supplement system designed to help ease the physical and emotional discomfort of withdrawal -- has announced its launch into Canada and Australia. Countries in the U.K., Europe and South America are expected to follow later in...

2014-01-09 12:26:30

CORALVILLE, Iowa, Jan. 9, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase(TM) 2014 Conference being held in San Francisco January 13-15, 2014. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

FDA Warning Issued On ADHD Drug Due To Painful Priapism
2013-12-17 15:58:44

Brett Smith for redOrbit.com - Your Universe Online A type of stimulant used to treat attention deficit disorders can lead to the development of long-lasting and sometimes painful erections, the Food and Drug Administration (FDA) said in a written warning released on Tuesday. The condition, referred to as priapism, was linked in an FDA review to males between 8 to 33 years of age who took drugs containing methylphenidate, the active ingredient in Ritalin and Concerta. “Patients who...

2013-12-12 23:03:30

Authors of an article featured in the current issue of Weed Technology collected waterhemp seed samples across Missouri to identify factors leading to glyphosate resistance. Over two-thirds of the weed sampled from soybean fields were shown to be resistant to the herbicide. Lawrence, KS (PRWEB) December 12, 2013 Weed Technology –Waterhemp is one of the most common weed species found in Midwest field crops. A member of the pigweed (Amaranth) family, this summer annual is capable of...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related